drugset / Trial / NCT06967181
A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this trial is to evaluate the safety and immunogenicity of CVM150 and CVM26. The trial will enroll up to 60 healthy participants.
Timeline
- Start
- 2025-05-14
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVM150 | Vaccine | — | Intranasal |
| Subject | CVM26 | Vaccine | — | Intranasal |